MRK Stock Overview
Merck KGaA operates as a science and technology company in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for MRK from our risk checks.
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €154.80 |
| 52 Week High | €172.15 |
| 52 Week Low | €134.55 |
| Beta | 0.67 |
| 1 Month Change | -3.13% |
| 3 Month Change | 5.38% |
| 1 Year Change | -3.34% |
| 3 Year Change | 6.32% |
| 5 Year Change | 62.84% |
| Change since IPO | 898.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.4% | 2.5% | 1.8% |
| 1Y | -3.3% | -27.7% | 2.2% |
Return vs Industry: MRK exceeded the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: MRK underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months.
Volatility Over Time: MRK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 62,908 | Belen Garijo Lopez | www.emdgroup.com |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Merck KGaA Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | €66.80b |
| Earnings (TTM) | €2.82b |
| Revenue (TTM) | €20.99b |
23.7x
P/E Ratio3.2x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | €20.99b |
| Cost of Revenue | €8.56b |
| Gross Profit | €12.44b |
| Other Expenses | €9.61b |
| Earnings | €2.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 6.50 |
| Gross Margin | 59.23% |
| Net Profit Margin | 13.45% |
| Debt/Equity Ratio | 35.2% |
How did MRK perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield34%
Payout RatioDoes MRK pay a reliable dividends?
See MRK dividend history and benchmarks| Merck KGaA dividend dates | |
|---|---|
| Ex Dividend Date | Apr 29 2024 |
| Dividend Pay Date | May 02 2024 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 8 days |
Does MRK pay a reliable dividends?
See MRK dividend history and benchmarks